Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Rational design of dually active inhibitors against human immunodeficiency virus (HIV) reverse transcriptase (RT) and integrase (IN) has proved viable with 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) type of non-nucleoside RT inhibitors (NNRTIs). To establish the pharmacophore and study the structure-activity relationships (SAR) of integrase inhibition within a previously disclosed RT/IN dual inhibitor scaffold, new analogues featuring substitution at different sites of the HEPT ring were designed and synthesized. These studies have revealed an IN inhibition pharmacophore that is merged with the known RT pharmacophore through a shared C-6 benzyl group. Further SAR also demonstrated that optimal IN inhibition within our dual inhibitor scaffold requires a regiospecific (N-1) diketoacid (DKA)-carrying pendant with a certain length.

Original languageEnglish (US)
Pages (from-to)4202-4211
Number of pages10
JournalBioorganic and Medicinal Chemistry
Volume18
Issue number12
DOIs
StatePublished - Jun 15 2010

Bibliographical note

Funding Information:
This research was supported by the Center for Drug Design at the University of Minnesota . We thank Dr. Yuk Sham for helpful discussion, Daniel Wilson for assistance in IN assay, Roger Ptak at Southern Research Institute for cell-based HIV assay, Dr. Robert Craigie of NIH for the integrase plasmid and Dr. William Shannon for consultation.

Keywords

  • Diketoacid
  • HIV
  • Integrase
  • Pharmacophore
  • SAR

Fingerprint

Dive into the research topics of 'Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase'. Together they form a unique fingerprint.

Cite this